Kramer K K, Zoelle J T, Klaassen C D
Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City 66160-7417, USA.
Toxicol Appl Pharmacol. 1996 Nov;141(1):1-7. doi: 10.1006/taap.1996.0253.
Metallothionein (MT)-I and -II are present in most if not all cells of the body and are readily inducible both in vivo and in vitro. MT-III is present only in brain, primarily in neurons, and is seemingly not inducible. Because it is difficult to determine whether inducing agents reach neurons (in vivo) in sufficient concentrations, it was of interest to directly test the inducibility of MT-III in vitro. A further objective was to examine the inducibility of MT-I and -II so that comparisons could be made to responses in glial cells. Cultures were established from fetal (Days 14-17) CF-1 mice. Cells were treated after they achieved a mature phenotype (around 6 days) with various concentrations of the following MT inducers: dexamethasone (Dex), cadmium (Cd), zinc (Zn), or inorganic mercury (Hg). MT protein was quantified by the Cd-hemoglobin assay at 24, 48, 72, 96, and 120 hr. All inducers produced significant increases in MT protein between 24 and 96 hr. MT protein increased in a dose-dependent manner, and maximum (up to 6-fold over controls) increases were seen at 3, 30, 100, and 1000 microM for Cd, Hg, Zn, and Dex, respectively. The expression of MT-I, -II, and -III mRNA was examined by dot-blot analysis 6 hr following the addition of inducers at concentrations known to maximally stimulate the induction of MT protein. Zinc and Cd produced 2.5 to 3.5-fold increases in MT-I and -II mRNA, whereas Dex and Hg produced 1.5- to 2.5-fold increases. However, all inducers assayed decreased MT-III mRNA about 30-60%. The present results indicate that MT-I and -II are inducible in neurons as they are in astrocytes, but the basal level and induced level of MT protein is about one-third in neurons as in astrocytes. Unlike MT-I and -II, MT-III is apparently not inducible under the present experimental conditions.
金属硫蛋白(MT)-I和-II存在于人体的大多数(即便不是全部)细胞中,并且在体内和体外都易于被诱导产生。MT-III仅存在于大脑中,主要存在于神经元中,且似乎无法被诱导产生。由于难以确定诱导剂在体内是否能以足够的浓度到达神经元,因此直接在体外测试MT-III的可诱导性很有意义。另一个目标是检测MT-I和-II的可诱导性,以便与胶质细胞中的反应进行比较。从胎龄14 - 17天的CF-1小鼠建立细胞培养物。细胞在达到成熟表型(约6天)后,用以下不同浓度的MT诱导剂进行处理:地塞米松(Dex)、镉(Cd)、锌(Zn)或无机汞(Hg)。在24、48、72、96和120小时时,通过镉 - 血红蛋白测定法定量MT蛋白。所有诱导剂在24至96小时之间均使MT蛋白显著增加。MT蛋白呈剂量依赖性增加,镉、汞、锌和地塞米松分别在3、30、100和1000微摩尔浓度时出现最大增加(比对照高6倍)。在添加已知能最大程度刺激MT蛋白诱导的浓度的诱导剂6小时后,通过点杂交分析检测MT-I、-II和-III mRNA的表达。锌和镉使MT-I和-II mRNA增加2.5至3.5倍,而地塞米松和汞使MT-I和-II mRNA增加1.5至2.5倍。然而,所有检测的诱导剂均使MT-III mRNA降低约30 - 60%。目前的结果表明,MT-I和-II在神经元中与在星形胶质细胞中一样可被诱导,但神经元中MT蛋白的基础水平和诱导水平约为星形胶质细胞中的三分之一。与MT-I和-II不同,在目前的实验条件下,MT-III显然无法被诱导。